Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedFeb 03, 2026
DataAggregated Company Financials
Companies5
  • 7D-0.7%
  • 3M2.2%
  • 1Y15.4%
  • YTD1.6%

Over the last 7 days, the Biotech industry has dropped 3.3%, driven by Genmab declining 0.9%. This takes the industry's 12 month performance to a gain of 12%. As for the next few years, earnings are forecast to decline by 5.9% per annum.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 03 Feb 2026DKK 174.2bDKK 40.4bDKK 18.9b6.1x9.2x4.3x
Thu, 01 Jan 2026DKK 173.2bDKK 40.5bDKK 19.0b6.1x9.1x4.3x
Sat, 29 Nov 2025DKK 176.9bDKK 40.8bDKK 19.1b5.9x9.3x4.3x
Mon, 27 Oct 2025DKK 169.9bDKK 39.0bDKK 16.8b13.3x10.1x4.4x
Wed, 24 Sep 2025DKK 163.1bDKK 38.6bDKK 16.7b12.7x9.8x4.2x
Fri, 22 Aug 2025DKK 145.0bDKK 38.8bDKK 16.7b11x8.7x3.7x
Sun, 20 Jul 2025DKK 128.1bDKK 27.1bDKK 7.4b11.4x17.4x4.7x
Tue, 17 Jun 2025DKK 135.1bDKK 27.2bDKK 7.4b11.5x18.2x5x
Thu, 15 May 2025DKK 122.3bDKK 28.0bDKK 7.9b9.8x15.5x4.4x
Sat, 12 Apr 2025DKK 120.0bDKK 27.3bDKK 7.7b10.7x15.6x4.4x
Mon, 10 Mar 2025DKK 156.9bDKK 27.3bDKK 7.7b13.3x20.4x5.7x
Wed, 05 Feb 2025DKK 153.7bDKK 26.0bDKK 4.7b15.3x32.7x5.9x
Fri, 03 Jan 2025DKK 165.1bDKK 26.0bDKK 4.7b17.3x35.2x6.3x
Sun, 01 Dec 2024DKK 164.4bDKK 26.0bDKK 4.7b17.1x35x6.3x
Tue, 29 Oct 2024DKK 177.1bDKK 25.5bDKK 5.5b21.2x32.4x6.9x
Thu, 26 Sep 2024DKK 183.9bDKK 25.5bDKK 5.5b22.6x33.6x7.2x
Sat, 24 Aug 2024DKK 200.1bDKK 25.5bDKK 5.5b25.7x36.7x7.8x
Mon, 22 Jul 2024DKK 195.0bDKK 24.8bDKK 5.6b18.2x34.6x7.9x
Wed, 19 Jun 2024DKK 168.7bDKK 24.8bDKK 5.6b16.8x29.9x6.8x
Fri, 17 May 2024DKK 183.6bDKK 25.2bDKK 6.2b16.5x29.8x7.3x
Sun, 14 Apr 2024DKK 183.5bDKK 23.9bDKK 5.0b19.4x36.4x7.7x
Tue, 12 Mar 2024DKK 196.3bDKK 23.9bDKK 5.0b20.5x39x8.2x
Thu, 08 Feb 2024DKK 168.5bDKK 23.3bDKK 4.2b23.2x40.5x7.2x
Sat, 06 Jan 2024DKK 177.7bDKK 23.3bDKK 4.2b26x42.7x7.6x
Mon, 04 Dec 2023DKK 173.8bDKK 23.3bDKK 4.2b25.2x41.8x7.5x
Wed, 01 Nov 2023DKK 158.1bDKK 22.0bDKK 4.7b18.5x33.4x7.2x
Fri, 29 Sep 2023DKK 192.8bDKK 22.0bDKK 4.7b22.7x40.7x8.8x
Sun, 27 Aug 2023DKK 196.4bDKK 22.0bDKK 4.7b23.3x41.6x8.9x
Tue, 25 Jul 2023DKK 200.9bDKK 19.5bDKK 4.4b34.9x45.6x10.3x
Thu, 22 Jun 2023DKK 200.7bDKK 19.5bDKK 4.4b42.4x45.6x10.3x
Sat, 20 May 2023DKK 216.2bDKK 19.5bDKK 4.4b44.1x49.1x11.1x
Mon, 17 Apr 2023DKK 212.7bDKK 17.9bDKK 3.5b33.3x60.1x11.9x
Wed, 15 Mar 2023DKK 190.9bDKK 17.9bDKK 3.5b29.6x53.9x10.7x
Fri, 10 Feb 2023DKK 209.7bDKK 14.7bDKK 3.3b32.1x64.1x14.2x
Price to Earnings Ratio

64.1x


Total Market Cap: DKK 209.7bTotal Earnings: DKK 3.3bTotal Revenue: DKK 14.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 32.2x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.0x which is lower than its 3-year average PE of 32.2x.
  • The 3-year average PS ratio of 7.2x is higher than the industry's current PS ratio of 4.2x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 79% per year over the last three years.
  • Revenues for these companies have grown 40% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-1.69%
Healthcare-5.16%
Biotech-0.66%
Biotech-0.66%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ZEAL Zealand PharmaDKK 427.502.3%
+DKK 669.2m		-39.6%PE4.6x

Latest News

ZEAL
DKK 427.50
Zealand Pharma
7D
2.3%
1Y
-39.6%

ZEAL: Metabolic Collaboration Will Support Future Upside As Margins Strengthen

Analysts see Zealand Pharma’s fair value estimate broadly unchanged at around €745.93 per share. The updated target reflects slightly firmer profit margin assumptions at 26.94%, a modestly smaller 36.49% revenue decline, and a lower forward P/E of 94.77x, partly offset by a marginally higher 5.17% discount rate.
BAVA
DKK 191.55
Bavarian Nordic
7D
-3.7%
1Y
2.4%

BAVA: Vaccine Preparedness Contracts And Buybacks Will Support Stronger Long Term Earnings

Analysts have kept their price target for Bavarian Nordic steady at €250.00. They cite a slightly higher assumed discount rate, a smaller expected revenue decline of around 5%, a higher projected profit margin of about 17%, and a lower future P/E assumption near 23x as key inputs behind the unchanged view.
GMAB
DKK 2,090.00
Genmab
7D
-0.9%
1Y
50.0%

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
BIOPOR
DKK 0.99
BioPorto
7D
-1.5%
1Y
-31.9%
STRAP
DKK 650.00
Strategic Partners
7D
-7.7%
1Y
-22.1%